Multidrug-resistant Klebsiella pneumoniae in hospital-acquired infections: Concomitant analysis of antimicrobial resistant strains

Int J Clin Pract. 2020 Apr;74(4):e13463. doi: 10.1111/ijcp.13463. Epub 2019 Dec 18.

Abstract

Background: Hospital-acquired infections caused by K pneumoniae are difficult to eradicate since K pneumoniae carries resistance genes for many antimicrobials, including carbapenems. The study aimed to determine the prevalence of hospital-acquired infections caused by multiple drug-resistant K pneumoniae and identify carbapenem and fluoroquinolone resistance by phenotypic and genotypic methods amongst hospitalised patients.

Methods: Two hundred and fifty samples from patients with hospital-acquired infections were included. Identification and susceptibility testing for K pneumoniae isolates was performed by standard methods. The detection of carbapenemase resistance (blaKPC , blaVIM-1 and blaOXA-48 ) and plasmid-mediated quinolone resistance (PMQR; qnrA, qnrB and qnrS) genes was performed using PCR assay.

Results: Out of 250 samples, 42 (16.8%) were multiple drug-resistant K pneumoniae, and the frequency of K Pneumoniae isolation was higher in urine samples, in the age group (<10 years), in ICU and in patients with longer hospital stay. Twenty-four (57%) of the isolates were resistant to Meropenem, 13 (31%) were resistant to Imipenem and 35 (83.3%) were resistant to Ciprofloxacin. blaOXA-48 gene was detected in 9 (21.4%) of isolates, and blaVIM-1 gene was detected in 6 (14.3%) of isolates. However, no isolate harboured blaKPC gene. PMQR genes were detected in 100% of ciprofloxacin resistant isolates, and qnrS was the dominant.

Conclusion: Multidrug-resistant K pneumoniae isolates harbouring blaOXA-48, blaVIM-1 and PMQR genes are emerging in hospitals particularly with long hospital stays.

Keywords: K pneumoniae; PMQR; carbapenem-resistant; hospital-acquired infection; multidrug-resistance; prevalence.

MeSH terms

  • Adolescent
  • Adult
  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use
  • Bacterial Proteins / genetics*
  • Child
  • Ciprofloxacin / pharmacology
  • Ciprofloxacin / therapeutic use
  • Cross Infection / drug therapy
  • Cross Infection / microbiology*
  • Drug Resistance, Multiple, Bacterial / genetics
  • Female
  • Genotype
  • Humans
  • Imipenem / pharmacology
  • Imipenem / therapeutic use
  • Klebsiella Infections / drug therapy
  • Klebsiella Infections / microbiology*
  • Klebsiella pneumoniae / drug effects*
  • Klebsiella pneumoniae / genetics
  • Length of Stay
  • Male
  • Meropenem / pharmacology
  • Meropenem / therapeutic use
  • Microbial Sensitivity Tests
  • Middle Aged
  • Phenotype
  • Young Adult
  • beta-Lactamases / genetics*

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Qnr protein, Klebsiella pneumoniae
  • Ciprofloxacin
  • Imipenem
  • beta-Lactamases
  • Meropenem